Search Results

FACT-B+4 Functional Assessment of Cancer Therapy – Lymphedema For patients with Lymphedema (to be used with FACT-B) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-B+4 measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Lymphedema (FACT-B+4) VERSION: 4 NUMBER OF ITEMS: 41 PATIENT POPULATION: Breast cancer patients 18 years and older with lymphedema RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Breast Cancer Subscale, Lymphedema Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-B , NFBSI-16 , FBSI-8 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-B+4 can be obtained by registering for permission. Users are not permitted to translate the FACT-B+4 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-B+4 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Andrade Ortega JA, Millán Gómez AP, Ribeiro González M, Martínez Piró P, Jiménez Anula J, Sánchez Andújar MB. Validation of the FACT-B+4-UL questionnaire and exploration of its predictive value in women submitted to surgery for breast cancer. Med Clin (Barc). 2017 Jun 21;148(12):555-558. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Coster, S., Poole, K. & Fallowfield, L.J. The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively. Breast Cancer Res Treat 68, 273–282 (2001). Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-B Functional Assessment of Cancer Therapy – Breast LEARN MORE NFBSI-16 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Breast Cancer Symptom Index - 16 Item Version LEARN MORE FBSI-8 FACT Breast Symptom Index LEARN MORE

FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy For patients receiving radionuclide therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a standardized measure to monitor relevant symptoms and toxicities among prostate cancer patients in RNT trials and clinical settings. It was developed first by identifying relevant symptoms and toxicities by reviewing published trials and interviewing prostate cancer patients receiving radionuclide therapy (n=529), caregivers (n=514), and clinicians (n=511), then by selecting items for inclusion. The item list was refined with input from experts in RNTs and patient reported outcomes measures. MEASURE NAME: Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) VERSION: 1 NUMBER OF ITEMS: 15 PATIENT POPULATION: Patients receiving radionuclide therapy (RNT) for prostate cancer aged 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: RNT TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible. RELATED MEASURES: FACT-P , NFPSI-17 , FPSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-RNT can be obtained by registering for permission. Users are not permitted to translate the FACT-RNT without permission from FACIT.org. Permission from FACIT.org to translate the FACT-RNT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946. Epub ahead of print. PMID: 36635088. LICENSE THIS MEASURE Related Measures Related Measures FACT-P Functional Assessment of Cancer Therapy – Prostate LEARN MORE NFPSI-17 NCCN/FACT Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FPSI FACT Prostate Cancer Symptom Index - 7 Item Version LEARN MORE

Download scoring documents for this measure. BACK FACT-V Scoring Downloads Download DOC

FACT-En Functional Assessment of Cancer Therapy – Endometrial For patients with Endometrial cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-En measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Endometrial (FACT-En) VERSION: 4 NUMBER OF ITEMS: 43 PATIENT POPULATION: Endometrial cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Endometrial Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-Cx , FACT-V , FACT-O DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-En can be obtained by registering for permission. Users are not permitted to translate the FACT-En without permission from FACIT.org. Permission from FACIT.org to translate the FACT-En may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Cx Functional Assessment of Cancer Therapy – Cervix LEARN MORE FACT-V Functional Assessment of Cancer Therapy – Vulva LEARN MORE FACT-O Functional Assessment of Cancer Therapy – Ovarian LEARN MORE

FAMS Functional Assessment of Multiple Sclerosis LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FAMS measure: MEASURE NAME: Functional Assessment of Multiple Sclerosis (FAMS) VERSION: 4 NUMBER OF ITEMS: 58 PATIENT POPULATION: Multiple sclerosis patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Mobility, Symptoms, Emotional Well-Being, General Contentment, Thinking and Fatigue, Family/Social Well-Being, Additional Concerns TIME FOR COMPLETION: 15-20 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FAHI , FACIT-Dyspnea , FACIT-TB DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAMS can be obtained by registering for permission. Users are not permitted to translate the FAMS without permission from FACIT.org. Permission from FACIT.org to translate the FAMS may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D.F., Dineen, K., Arnason, B., Reder, A., Webster, K.A., Karabatsos, G., Chang, C., Lloyd, S., Mo, F., Stewart, J., & Stefoski, D. Validation of the Functional Assessment of Multiple Sclerosis Quality of life instrument. Neurology 1996; 47: 129-139. doi: 10.1212/WNL.47.1.129. Fischer, J., LaRocca, N., Miller, D., Ritvo, P., Andrews, H. & Paty, D. Recent developments in the assessment of quality of life in Multiple Sclerosis (MS). Multiple Sclerosis 1999; 5(4): 251-259. doi: 10.1177/135245859900500410. Kossakowska, M. Standaryzacja polskiej wersji Kwestionariusza do Oceny Jakości Życia w Stwardnieniu Rozsianym (FAMS). Psychologia Jakości Życia , 2004; 3(1): 61-80. Riazi, A., Hobart, J., Lamping, D., Fitzpatrick, R., & Thompson, A. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Multiple Sclerosis 2003; 9; 411-419. doi: 10.1191/1352458503ms929oa. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FAHI Functional Assessment of HIV Infection LEARN MORE FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE FACIT-TB Functional Assessment of Chronic Illness Therapy - Tuberculosis LEARN MORE

View all available languages for this measure. BACK NFCSI-19 Languages English Hebrew Romanian Spanish

View all available languages for this measure. BACK FBSI Languages Afrikaans Arabic Armenian Bengali Bosnian Bulgarian Burmese Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French German Greek Gujarati Haitian Creole Hebrew Hindi Hungarian Indonesian Italian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version For patients with Kidney Cancer, a 10 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FKSI-10 measure: MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version (FKSI-10) VERSION: 4 NUMBER OF ITEMS: 10 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. RELATED MEASURES: FKSI-15 , NFKSI-19 , FKSI-DRS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-10 can be obtained by registering for permission. Users are not permitted to translate the FKSI-10 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-10 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., George, J., Bro, W., Kelly, C., & Bukowski, R. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Journal of Supportive Oncology 2006; 4(4):191-199. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE

OMDQ Oral Mucositis Daily Questionniare A daily measure for patients with oral mucositis LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Originally developed by Amgen in conjunction with clinical studies in support of palifermin, the OMDQ is a reliable, valid, and responsive patient-reported measure of oral mucositis severity. While multiple variants of the OMDQ/OMWQ have been published, the version licensed by FACIT.org is the official, final version developed by Amgen. MEASURE NAME: Oral Mucositis Daily Questionniare (OMDQ) VERSION: 2 NUMBER OF ITEMS: 5 PATIENT POPULATION: Oral mucositis patients 18 years and older RECALL PERIOD: Past 24 hours RESPONSE SCALE: Various DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: Not available SCORING: Manual scoring template RELATED MEASURES: OMWQ , FACT-HN , NFHNSI-22 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the OMDQ can be obtained when licensing the measure. Users are not permitted to translate the OMDQ without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the OMDQ. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, Lu ZJ, Spielberger R. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006 Feb;37(4):393-401. doi: 10.1038/sj.bmt.1705250. PMID: 16415901. LICENSE THIS MEASURE Related Measures Related Measures OMWQ Oral Mucositis Weekly Questionnaire LEARN MORE FACT-HN Functional Assessment of Cancer Therapy – Head and Neck LEARN MORE NFHNSI-22 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version LEARN MORE

Download this measure in English. BACK FACT-G English Downloads Download PDF Download DOC

FACT-O Functional Assessment of Cancer Therapy – Ovarian For patients with Ovarian cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Ovarian (FACT-O) provides a reliable and valid assessment of the quality of life of women with ovarian cancer, and is appropriate as a brief quality of life assessment in clinical trials and descriptive studies. It was initially validated with 232 ovarian cancer patients attending an outpatient gynecologic oncology clinic, who completed the measure at baseline. The patients’ FACT-O scores were then compared with their performance status, disease stage, treatment status, and other factors hypothesized to be related to quality of life. Patients received a second measure either one week after baseline to assess the instrument’s test-retest reliability and/or two months after baseline to evaluate its sensitivity to change in performance status. Overall, the subscales correlated with other measures as expected; all correlations were in the hypothesized direction. Patients with advanced disease, poor performance status, and who were receiving active treatment had lower scores on physical, functional, and ovarian cancer-specific scales. The total FACT-O and emotional well-being scores were lower for patients with poor performance status and patients in active treatment. The FACT-O total and all subscale scores except emotional well-being were sensitive to decreases in performance status. MEASURE NAME: Functional Assessment of Cancer Therapy – Ovarian (FACT-O) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Ovarian cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Ovarian Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FOSI , NFOSI-18 , FACT-Cx DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-O can be obtained by registering for permission. Users are not permitted to translate the FACT-O without permission from FACIT.org. Permission from FACIT.org to translate the FACT-O may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Basen-Engquist, K., Bodurka-Bevers D., Fitzgerald M., Webster K., Cella D., Hu S., & Gershenson D. Reliability and Validity of the Functional Assessment of Cancer Therapy-Ovarian. The Journal of Clinical Oncology 2001; 19(6): 1809-1817. doi: 10.1200/jco.2001.19.6.1809. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FOSI Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 8 Item Version LEARN MORE NFOSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 18 Item Version LEARN MORE FACT-Cx Functional Assessment of Cancer Therapy – Cervix LEARN MORE